Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHBY)
:RHHBY
Holding RHHBY?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
1.21Last Year’s EPS
1.23Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 31, 2019
|% Change Since: -4.85%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in core operating profit, strong performance in the Pharma and Diagnostics divisions, and multiple regulatory achievements. However, there were challenges in the Japanese market, discontinuation of key studies, and impacts from COVID-19 and loss of exclusivity.Company Guidance
During the second quarter of 2024, Roche Group reported an impressive sales growth of 9%, driven by an 8% increase in Pharma and a 9% rise in Diagnostics, excluding the impact of COVID-19. The company saw a CHF 0.8 billion decrease in COVID-19 sales and a CHF 0.6 billion loss due to loss of exclusivity (LOE), both aligning with earlier guidance. Core operating profit surged by 11%, contributing to a nearly 2-percentage-point increase in the core operating margin. Core EPS and operating cash flow both rose by 9%. The company achieved several regulatory milestones, including EU approval for Ocrevus subcutaneous in RMS and PPMS and U.S. approval for a biosimilar prefilled syringe. Diagnostic launches, such as the cobas lead respiratory panel, further bolstered growth prospects. Roche aims to maintain strong growth momentum into 2025, with a confirmed group sales outlook and an upgraded high single-digit growth projection for core EPS.Strong Revenue Growth
Group sales increased by 8% excluding COVID, with Pharma at 8% and Diagnostics at 9%.
Core Operating Profit Surge
Core operating profit increased by 11%, driven by good cost management.
Regulatory Achievements
Multiple approvals including Ocrevus subcutaneous in EU, Alecensa in adjuvant ALK-positive non-small cell lung cancer, and FDA label update for Susvimo in AMD.
Diagnostics Segment Growth
Diagnostics sales increased by 5%, with strong growth in core lab and pathology lab segments.
Obesity Market Potential
Positive Phase I data for obesity treatments CT-388 and CT-996, with potential best-in-class profile.
---
RHHBY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RHHBY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jul 25, 2024 | $38.54 | $39.56 | +2.65% |
| Feb 01, 2024 | $34.24 | $33.44 | -2.34% |
| Jul 27, 2023 | $38.15 | $37.88 | -0.71% |
| Feb 02, 2023 | $36.51 | $35.88 | -1.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Roche Holding AG (RHHBY) report earnings?
Roche Holding AG (RHHBY) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Roche Holding AG (RHHBY) earnings time?
Roche Holding AG (RHHBY) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RHHBY EPS forecast?
RHHBY EPS forecast for the fiscal quarter 2024 (Q4) is 1.21.
---